Comments
Venus Remedies Ltd.’s shares were up by 3.59 per cent after the company secured Saudi’s approval for Enoxaparin in pre-filled syringes. This enhances its presence in Saudi Arabia, the GCC’s largest pharmaceutical market, and opens doors to GCC and MENA countries.
Enoxaparin addresses blood clot issues, which is vital in Saudi Arabia, where cardiovascular diseases are a concern. The global Enoxaparin market is projected to reach $5.35 billion by 2028.
Venus Remedies supplied $12 million worth of Enoxaparin globally during the COVID-19 pandemic, aided by an 80 per cent capacity boost from a new robotic line.
The shares of the company were up by 3.59 to Rs. 241 at 12.29 p.m. on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.